• bit.bio has undertaken a COVID-19 risk assessment and we are COVID secure
bit.bio
  • technology
  • about
    • who we are
    • team
    • careers
    • partner with us
  • products
    • ioGlutamatergic Neurons
    • ioSkeletal Myocytes
  • resources
    • webinars
    • posters
    • journals
    • videos
  • news
  • events
  • contact
Select Page
A novel human skeletal muscle in vitro model using opti-ox™ mediated cellular reprogramming of induced pluripotent stem cells

A novel human skeletal muscle in vitro model using opti-ox™ mediated cellular reprogramming of induced pluripotent stem cells

POSTER A novel human skeletal muscle in vitro model using opti-ox™ mediated cellular reprogramming of induced pluripotent stem cells Bernard, et al. 2020. bit.bio   We have developed an optimised inducible system (opti-ox™) that enables tightly controlled...
High Content Analysis of 2D and 3D cellular models for target and phenotypic drug discovery

High Content Analysis of 2D and 3D cellular models for target and phenotypic drug discovery

POSTER High Content Analysis of 2D and 3D cellular models for target and phenotypic drug discovery Lachize, et al. 2020. Courtesy of Charles River   Charles River Laboratories (CRL) has developed many disease-relevant cellular models to screen small molecules and...
Optimized reprogramming of human iPSCs to generate distinct neuronal subtypes

Optimized reprogramming of human iPSCs to generate distinct neuronal subtypes

POSTER Optimized reprogramming of human iPSCs to generate distinct neuronal subtypes Karim, et al. 2020. bit.bio   A robust source of human iPSC-derived neurons would offer an attractive in vitro model for CNS research and high content drug screens. However,...
Molecular and functional characterization of stem cells-derived glutamatergic neurons in support of drug discovery applications

Molecular and functional characterization of stem cells-derived glutamatergic neurons in support of drug discovery applications

POSTER Molecular and functional characterization of stem cells-derived glutamatergic neurons in support of drug discovery applications Iovino, et al. 2019. Courtesy of Charles River Charles River has performed molecular and functional characterization of human...

Latest news

  • bit.bio newsLeading clinical immunotherapies developer Ramy Ibrahim joins bit.bio as Chief Medical Officer
  • bit.bio CEO discusses opti-ox technology and the work of bit.bio on BBC Clickbit.bio CEO discusses opti-ox™ technology and the work of bit.bio on BBC Click
  • bit.bio, a UK synthetic biology startupCan We Recreate Every Human Cell Type In The Body? This UK Startup Thinks So
  • Bit.Bio has received £40 million of backing for technology that it says can reliably reprogram stem cells to make any human cell desiredBit.Bio: British firm cracks code for stem cells
  • bit.bio partners with LIMSbit.bio joins forces with maths institute to find the ‘operating system of life’

Navigation

technology
about
careers
partner with us
resources
news
events
contact

 

ioGlutamatergic Neurons
ioSkeletal Myocytes

 

Products

ioGlutamatergic Neurons
ioSkeletal Myocytes

 

Subscribe to our newsletter





    Please confirm that we may add you to our mailing list, and send you our latest news and updates:
    Yes, please email me
    You can unsubscribe at any time by clicking the link in the footer of our emails. Learn more about our privacy practices here.

    This site is protected by reCAPTCHA and the Google Privacy Policy and Terms apply.

    bit.bio © 2021 | All rights reserved | privacy policy | terms & conditions

    bit.bio © 2021 | All rights reserved
    privacy policy | terms & conditions